Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, enters into a definitive merger agreement to be acquired by Endo International plc for a combination of cash and stock.
On October 8, Willkie client Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, entered into a definitive merger agreement to be acquired by Endo International plc for a combination of cash and stock which values Auxilium at approximately $2.6 billion. The signing of the merger agreement follows Auxilium’s receipt on September 12 of an unsolicited, non-binding proposal from Endo. In connection with the signing of the merger agreement, the board of directors of Auxilium determined that the merger agreement with Endo constituted a superior proposal under the terms of Auxilium’s existing merger agreement with QLT Inc. and terminated the QLT merger agreement.
Auxilium Pharmaceuticals, Inc. is a fully integrated specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specialist audiences. Willkie recently represented the company in its $657 million acquisition of Actient Holdings LLC, a private urology specialty therapeutics company.
The current matter is being handled by partners Adam Turteltaub, Russell Leaf, Tariq Mundiya, Sameer Advani, Michael Schwartz, Thomas Meloro, William Hiller and Jordan Messinger, special counsel Jonathan Konoff, and associates Theodore Powers, Jonathan Kubek, Kristin Toppeta, Christina Castedo, Daniel Philion, Geri Anne McEvoy, Robert Larimore, Sara O’Brien, and Jonathan McAlister.